The abstract is read at the publisher; the summary is JClub's.
Incretin-based therapies for adult obesity can improve weight and cardiometabolic outcomes, but reduced appetite and gastrointestinal effects may pose nutritional, functional, and psychological risks.
- Why it matters: The gap is translating these benefits into safe, individualized care, because appetite suppression, rapid weight loss, and eating-behaviour changes can threaten fat-free mass, function, and wellbeing in some people.
- What they did: The EASO-EFAD-ECPO Consensus Statement synthesizes evidence on medical nutrition therapy, including protein targets during weight loss, diet quality, and mitigation of gastrointestinal adverse events, plus psychological screening and monitoring.
- The result: It recommends pragmatic monitoring of diet quality, micronutrient risk, and functional measures (with body-composition assessment when indicated), alongside shared decision-making and integrated psychological support to improve safety and equity.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.